Description

BioMarin’s Boldest Bet Yet: Inside the $4.8 Billion Amicus Takeover!

BioMarin Pharmaceutical just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The move, announced in December 2025, marks BioMarin’s second major buyout of the year and is set to close in Q2 2026. The company will fund the transaction through $3.7 billion in nonconvertible debt and existing cash on hand. The motivation? A strategic expansion into Fabry and Pompe disease treatments, two rare but underpenetrated markets, with Amicus’s Galafold and Pompe therapies contributing nearly $600 million in revenue over the past year. Coming at a time when BioMarin is also sunsetting its gene therapy program ROCTAVIAN, this deal looks like a redirection of both capital and focus. Management promises immediate revenue accretion, stronger cash flows, and access to faster-growing portfolios. But beneath the surface, the BioMarin Amicus acquisition reflects more than just financial mechanics—it’s about synergy, global scale, and risk mitigation.